GlassScriptPhysician profile
Matthew J Levine
NPI 1801994231
$133,515.73
in general payments reported to CMS, 2019-2025
44 companies · $8,168 in 2025
The $8,168 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $25K · 2021: $24K · 2022: $20K · 2023: $8,576 · 2024: $8,770 · 2025: $8,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $3,895 · Consulting Fee: $1,313 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,291.75 |
| Food and Beverage | $3,894.80 |
| Consulting Fee | $1,312.50 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $83,044.05 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $23,477.48 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Ascendis Pharma Endocrinology INC | $7,036.61 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $5,120.58 | 2019-2020 | |
| Amgen INC. | $2,954.42 | 2019-2025 | Prolia, Evenity, Tepezza |
| Janssen Pharmaceuticals, INC | $2,579.10 | 2019-2020 | |
| Mannkind Corporation | $2,482.78 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $2,156.99 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $866.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.05 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $281.48 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $242.42 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $224.94 | 2019-2025 | Omnipod |
| Radius Health, INC. | $212.51 | 2019-2025 | |
| Dexcom, INC. | $205.54 | 2019-2025 | Dexcom G6 Transmitter |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $198.17 | 2019-2025 | |
| Becton, Dickinson and Company | $180.69 | 2019-2022 | |
| Antares Pharma, INC. | $168.40 | 2019-2024 | Xyosted, Tlando |
| Kyowa Kirin, INC. | $161.72 | 2023-2025 | |
| Corcept Therapeutics | $143.09 | 2019-2025 | Korlym |
| Verity Pharmaceuticals INC. | $128.81 | 2024-2025 | Tlando |
| Tandem Diabetes Care, INC. | $118.33 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $109.03 | 2019-2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $106.27 | 2023-2025 | |
| Companion Medical, INC. | $88.04 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $77.08 | 2023-2024 | |
| Medtronic, INC. | $70.25 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Shire North American Group INC | $62.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.79 | 2022-2024 | |
| Beta Bionics, INC. | $56.64 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Valeritas, INC. | $54.18 | 2019 | |
| Cequr Corporation | $51.30 | 2024-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $49.60 | 2019-2025 | Licart, Flector, Tirosint |
| Horizon Therapeutics Plc | $47.80 | 2020-2021 | |
| Sequel Med Tech, LLC | $36.11 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $34.10 | 2019-2025 | Arexvy |
| Ultragenyx Pharmaceutical INC. | $23.23 | 2023 | Crysvita |
| Madrigal Pharmaceuticals | $21.91 | 2025 | Rezdiffra |
| Sun Pharmaceutical Industries INC. | $19.31 | 2024 | |
| Chiesi USA, INC. | $18.62 | 2024 | Mycapssa |
| Vistapharm, INC. | $18.59 | 2021 | |
| Viiv Healthcare Company | $17.81 | 2024 | Cabenuva |
| Acella Pharmaceuticals, LLC | $15.96 | 2024 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.